The Hyderabad-based company Natco Pharma had announced that it launched the first generic version of Sofosbuvir in Nepal under its brand Hepcinat.
Sofosbuvir is used for chronic Hepatitis C infection and sold globally by Gilead Sciences, under its brand Sovaldi.
Natco priced its generic medicine at an MRP of ₹19,900 for a bottle of 28 tablets in Nepal, according to a release.
“Natco hopes to launch the product in India soon subject to approval from the Drugs Controller General of India (DCGI),’’ the company said.
Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its chronic Hepatitis C medicines in 91 developing countries.
Natco Pharma scrip gained 2.34 per cent on the Bombay Stock Exchange on Monday to close at ₹1,549.